Yield10 Q1 2024 net loss $2.5M, improves cash burn; milestone payments received

YIELD10 BIOSCIENCE, INC.

2024-Q1 EPS reported -$4.77 revenue$300,000

Cash at $1.6M (up from $1.1M Dec 2023); operating cash burn $0.9M vs $2.7M YoY.
Recognized $0.3M license revenue from VISION; received $2M initial payment, additional $1M milestone in May 2024.
Net loss $2.5M ($4.77 diluted share) compared to $3.8M ($18.16) in Q1 2023; results reflect 1-for-24 reverse split.
EPA approved INTERLINE herbicide for Camelina; USDA-APHIS cleared commercial planting of HT Camelina.
Building omega-3 Camelina seed inventory for aquafeed; patent granted for carbon fixation pathway and notice of allowance for yield trait C3004.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

YIELD10 BIOSCIENCE, INC. reported financial results for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Result: reported results

Exact text from the filing

On May 15, 2024, Yield10 Bioscience, Inc. issued a press release announcing the financial results for the three months ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001121702-24-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.